Zhang, Tao
Nanfang Hospital · Southern Medical University
3 papers on CoChatORCID 0000-0001-6643-4686
Most cited papers
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 469
- Verified
Designing a novel vacuum aspiration system to decellularize large-size enthesis with preservation of physicochemical and biological properties
Shi, Q., Chen, Y., Li, M., Zhang, T., Ding, S., Xu, Y., Hu, J., Chen, C., & Lu, H. (2020) · Annals of Translational Medicine
Tissue Engineering and Regenerative MedicineBone Tissue Engineering Materials
Cited by 16
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free